Posted Feb. 29, 2008 – Health experts say the new anti-HIV medication Etravirine will help improve the quality of life for HIV-positive and AIDS patients who’ve shown resistance to other drugs.
:: AD ::
“With the recent approval, we now have a new drug that shows antiviral activity in the face of resistance,” said Dr. Debbie Hagins, a family practitioner specializing in AIDS treatment. “It can suppress viral replication.”
Last month, the U.S. Food and Drug Administration (FDA) approved Etravirine for adults who have failed treatment with other antiretroviral drug therapies used to treat HIV/AIDS. This is an important development for African Americans, who make up nearly half of the new HIV cases nationwide.
After a while, many of the drugs used to stop the virus from growing within an infected person fail, leaving doctors with few choices to thwart the deadly and stubborn virus, Hagins explained. With the new drug approval comes another option in the arsenal of drugs doctors have at their disposal to hold HIV at bay, she said.
Sold under the trade name Intelence, Etravirine helps block an enzyme that the AIDS-causing virus needs to multiply, the FDA said in a statement.